We have spent two decades focusing on how, when and where to best treat heart attacks, a form of acute coronary syndromes (ACS) – from assessing if early coronary intervention benefits high-risk patients, to evaluating anti-inflammatory and aldosterone-block drugs in ACS patients, and more. Landmark studies in the ACS program include COMPLETE, RIVAL, AND OASIS 4 (CURE).